PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Hold Business Update and 2016 Financial Results Conference Call on March 3rd, 2017
LYON, France --(BUSINESS WIRE)--Feb. 28, 2017-- Regulatory News : ERYTECH (Paris:ERYP) (ADR:EYRYY) :, the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium
LYON, France --(BUSINESS WIRE)--Jan. 17, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs
View HTML
Toggle Summary Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Jan. 6, 2017-- Regulatory News : Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website :
View HTML
Top